Effect of citalopram on lower esophageal sphincter function

Effect of citalopram on fasting and postprandial lower esophageal sphincter function in healthy subjects: a double-blind, placebo-controlled, randomized, cross-over study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2016-000563-16-BE

Enrollment

Registered

2016-02-17

Start date

2016-06-09

Completion date

Unknown

Last updated

2021-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Increased lower esophageal sphincter pressure

Interventions

Trade Name: Cipramil 40 mg/ml Product Name: Cipramil 40 mg/ml Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: CITALOPRAM CAS Number: 59729-33-8 Concentration unit: mg/m

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age >18 and =65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: 1. History of any upper GI symptoms or GI surgery 2. Psychological disorders 3. Any drug history 4. Use of medication altering GI motility 5. Pregnant or nursing women

Design outcomes

Primary

Measure	Time frame
Main Objective: To investigate the effect of citalopram on fasting and postprandial lower esophageal sphincter function in healthy subjects;Secondary Objective: Not applicable;Primary end point(s): To determine the effect of citalopram on fasting and postprandial lower esophageal sphincter function in healthy subjects;Timepoint(s) of evaluation of this end point: After administration of citalopram	—

Measure

Time frame

Main Objective: To investigate the effect of citalopram on fasting and postprandial lower esophageal sphincter function in healthy subjects;Secondary Objective: Not applicable;Primary end point(s): To determine the effect of citalopram on fasting and postprandial lower esophageal sphincter function in healthy subjects;Timepoint(s) of evaluation of this end point: After administration of citalopram

—

Secondary

Measure	Time frame
Secondary end point(s): Not applicable;Timepoint(s) of evaluation of this end point: Not applicable	—

Countries

Belgium

Contacts

Public ContactTARGID

K.U. Leuven

brecht.vanhoutte@kuleuven.be3216330671

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026